Articles tagged with Molecular Targets
A newly discovered radionuclide-based agent (CB-2PA-NT) has shown high tumor uptake, sustained retention, and contrast in preclinical models. Targeting neurotensin receptors, CB-2PA-NT expands precision medicine for cancer diagnosis and treatment.
A study using molecular imaging found that individuals with obesity respond differently to food cues than normal-weight individuals, with altered connectivity between brain networks. The research offers valuable insights into potential medical interventions for obesity, including novel drug treatments and behavioral therapies.
Researchers at MD Anderson Cancer Center have engineered a new model of aggressive renal cell carcinoma, highlighting molecular targets and genomic events that trigger chromosomal instability. The loss of interferon receptor genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability.
The study investigates the effects of DPDT on human colon cancer HCT116 cells and non-tumorigenic MRC5 fibroblasts. The results show that DPDT preferentially targets HCT116 cells, inducing apoptosis and G2/M cell cycle arrest, likely through DNA topoisomerase I poisoning.
Researchers at the Beckman Institute developed a new purification system that uses an electrified version of dialysis to separate salt and other unnecessary particles from wastewater. The method saves money and saps 90% less energy than its counterparts, making it a promising solution for global water scarcity.
A new PET radiotracer called <sup> 18 </sup> F-Cholestify has been developed to visualize metabolic cholesterol clearance in the brain. The tracer successfully visualized brain cholesterol metabolism in rats, non-human primates, and humans, showing promising results for studying neurodegenerative diseases.
Researchers at Aarhus University have discovered a new method to activate the complement system using bispecific single-domain antibodies, termed BiCEs. These molecules can specifically target cancer cells and activate the complement system, leading to the killing of targeted cancer cells.
A study published in Cancers found that a combination of radiotherapy followed by immunotherapy is effective against oral malignant melanomas in dogs. The treatment strategy increased overall survival time compared to immunotherapy alone. Researchers are now exploring the optimal protocol for this therapy to increase its effectiveness.
The study found that drug-resistant Leishmania parasites have distinct protein production profiles compared to sensitive parasites, suggesting a global reprogramming of protein synthesis. This pre-emptive adaptation enables the parasite to quickly respond to the presence of the drug and survive when it is absent.
Researchers have identified anti-malarial properties in cancer drugs, offering a potential solution to the growing crisis of drug-resistant malaria. The study found that certain protein kinase inhibitors exhibited strong anti-malarial effects, highlighting a new approach to accelerating drug discovery.
Researchers developed Precious1GPT, a multimodal transformer-based approach for aging clock development and feature importance analysis. The model utilizes methylation and transcriptomic data to predict biological age and identify disease-related genes, providing a pathway for therapeutic drug discovery.
A review article proposes zero-waste methodologies to convert 100% of marine macroalgae (seaweed) into cosmetics ingredients using industrially available green technology. This enables the cosmetics industry to meet environmental sustainability and ESG requirements, while leveraging the potential of Brazilian seaweed.
The PanDrugs2 programme analyzes alterations in tumour genes, relates them to existing available drugs, and reports on the most suitable ones. It handles data on over 4,600 genes and 14,600 chemical compounds, generating information on around 74,000 associations between drugs and genes.
A team of scientists has identified a key player in the coupling between early transcription termination and RNA degradation. The ARS2 protein recruits ZC3H4, which interacts with the NEXT complex to target nascent transcripts for degradation.
CNRS scientists have identified a molecule that prevents parasites of Plasmodium from invading blood cells, paving the way for a new class of antimalarials. The discovery is based on the key role of myosin A in malaria infection and its inhibition by KNX-002.
Researchers are investigating methods to extract critical materials, including lithium for electric vehicle batteries and magnets for electric motors, from diverse water streams. By accelerating evaporation through porous photothermal materials, they aim to reduce energy intensity and improve supply chain security.
Researchers developed CrossDome, a tool that uses genetic and biochemical information to predict T-cell immunotherapy's impact on healthy cells. The tool identified high-risk candidates in cases where treatments mistakenly attacked heart cells.
A new review paper suggests ACSL4 status as a biomarker for breast cancer subtype classification and predictor of response to hormone-based therapies. The enzyme may also serve as a target for developing new treatment modalities in quadruple negative breast cancer.
Researchers developed a new method, photoacoustic spectral analysis (PASA), to analyze the tumor microenvironment without invasive procedures. The technique uses laser light and sound waves to identify different types of tumors with high accuracy.
A new study published in Aging-US has identified the p53-p16/RB-E2F-DREAM complex as a critical regulator of cellular senescence. The researchers found that this complex represses multiple target genes involved in cell cycle regulation, DNA repair, and chromatin structure, leading to the stability of the senescent arrest.
Researchers found a peptide from venomous fish Thalassophryne nattereri that controls lung inflammation and airway hyperreactivity. The molecule, TnP, inhibited cytokine production and prevented mucus-producing cell hyperplasia, making it a potential candidate for treating asthma.
CHOP researchers have developed stable, universal MHC-I molecules that can be produced rapidly at scale, allowing for the development of effective and universal immunotherapies. These engineered MHC-I molecules promote peptide exchange across multiple HLA allotypes, covering various forms.
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
Researchers developed a CRISPR/Cas9-based gene drive system targeting the Drosophila suzukii doublesex gene, resulting in female sterility and high transmission rates. Mathematical modeling predicts efficient population suppression with low release ratios.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
Scientists at University of Virginia Health System discovered a gene that acts as a master controller for immune tolerance, shedding light on how our immune systems are calibrated to prevent MS. The new understanding could lead to better, more targeted treatments.
A team of astronomers using the James Webb Space Telescope has detected complex organic molecules in a galaxy over 12 billion light-years away. The discovery suggests that the presence of these molecules does not necessarily indicate star formation, contradicting a long-held assumption.
A University of Virginia-led study challenges traditional understanding of associative polymers' behavior, revealing that reversible bonds slow down polymer movement without creating a rubbery network. This discovery has implications for materials used in sustainability, health, and engineering applications.
Researchers at the University of Zurich have developed a new class of antibiotics that target novel targets in bacterial metabolism, effectively fighting resistant bacteria. The peptides are highly effective, safe, and immune to resistance, offering hope for treating bacterial infections in patients.
A team of researchers found that a small population of nerve cells exists in everyone that could be coaxed to regrow, potentially restoring sight and movement. The discovery provides new insights into how axons grow and could lead to effective therapies for blindness, paralysis, and other disorders caused by nerve damage.
Researchers discovered two new psychrophilic species of bacteria with cold-adapted enzymes, which can be used in biotechnology to produce refrigerated foods, improve detergent quality, and remove pollutants from cold environments. The study was conducted in collaboration with Uruguayan scientists and supported by FAPESP.
Alternative gene splicing has been linked to an increased risk of alcohol use disorder (AUD), according to a recent study published in Molecular Psychiatry. The researchers identified 27 exon skipping events that may contribute to AUD risk, opening up new possibilities for finding new therapeutics.
A recent study led by UCLA researchers has identified a potential new strategy for treating glioblastoma by targeting a specific metabolic process in cancer cells. The study found that disrupting this process could make glioblastoma cells more vulnerable to cell death, offering hope for new treatment options.
Scientists have discovered that increasing expression of the RIT2 gene reduces alpha-synuclein accumulation and protects neurons from cell death in Parkinson's disease. This breakthrough offers hope for developing a simpler intervention to reduce risk of the disease.
Scientists at Temple University have developed a novel gene-editing strategy that disrupts the ability of HIV-1 virus to enter host cells by targeting a rare genetic disorder. This approach may offer another target for developing next-generation CRISPR technology for HIV elimination, while avoiding adverse effects on cell mortality.
Dr. John H. Bushweller's team at UVA Cancer Center is developing novel drugs to block abnormal proteins that cause pediatric leukemia. The new approach aims to improve efficacy and reduce toxicity, potentially leading to better patient outcomes.
Researchers developed a computational platform called IRIS to discover tumor antigens from alternative RNA splicing, expanding cancer immunotherapy targets. Hundreds of predicted TCR targets were found to be presented by human leukocyte antigen molecules.
Researchers developed predictive models to design RNA-binding inhibitors for disease treatment by regulating protein production. The study identified three key features for effective oligonucleotides: thermostability, serum resistance, and RNase H sensitivity.
Researchers at UCLA Jonsson Comprehensive Cancer Center have found a potential therapeutic target, IL-21, to reduce endocrine autoimmune side effects from checkpoint immunotherapy. A specific group of immune cells play a central role in this autoimmune attack and blocking IL-21 prevents thyroid autoimmunity.
Researchers at Purdue University have developed a technique to identify Parkinson's disease-linked proteins and their downstream pathways in urine samples using EVtrap technology. This noninvasive method may lead to widespread early diagnosis and intervention for neurodegenerative diseases, including cancer.
Researchers at Aarhus University discover how the SUC transporter recognizes sucrose and uses acid to power its sugar delivery. This breakthrough sheds light on how plants defend themselves from pests and could lead to new ways of protecting plants from harmful bugs.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
A new study reveals that cyclic AMP and cGMP bind to ion channels with distinct effects, shedding light on their roles in regulating cell functions. The findings could inspire new treatments for disorders involving ion channel malfunctions.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
Researchers at Mount Sinai have discovered a previously unknown way in which the brain and immune system interact in multiple sclerosis. They found that the inflammatory protein interleukin-3 (IL-3) coordinates this communication, inciting the recruitment of immune cells to the brain and exacerbating brain inflammation.
Researchers identified three novel dual-purpose therapeutic targets using PandaOmics, which could treat both aging and glioblastoma multiforme. The target hypotheses include cyclic nucleotide gated channel subunit alpha 3 (CNGA3), glutamate dehydrogenase 1 (GLUD1) and sirtuin 1 (SIRT1).
A new study presents a chronic wound murine model that characterizes the role of persistent senescent cell accumulation in delayed wound closure. The molecular profiles of senescent cells demonstrate the adverse influence of SASP factors, highlighting a potential root-cause-driven therapeutic strategy.
Researchers have identified ATAD3A as a molecular determinant that favors the development of head and neck cancer. The protein is involved in various cellular processes, including energy metabolism and apoptosis. Targeting ATAD3A could offer a novel approach to developing effective anti-cancer therapeutics.
A study identified a protein, UBE2C, present in brain metastases associated with worse disease prognosis. Researchers found that high levels of UBE2C increase the spread of tumor cells in the central nervous system.
A new Raman probe, 9CN-JCR, has been developed for detecting multiple enzyme activities in heterogeneous biological tissues. The probe exhibits high sensitivity and multiplexing ability, making it a promising tool for cancer diagnosis and research.
Researchers have discovered that manipulating Yes-associated protein (YAP) expression in liver progenitor cells can improve their ability to regenerate and repair liver tissue. This could lead to new treatments for chronic liver diseases.
Researchers at Washington State University have identified the Arrdc5 gene as a potential target for male contraception. The study found that when this gene is inactivated, it causes significant infertility in males, characterized by decreased sperm count, slowed mobility, and distorted shape.
Scientists have developed a method to activate protein functions using brief flashes of light, enabling precise control over when and where chemical reactions occur. This technology has potential uses in tissue engineering, regenerative medicine, and understanding biological processes.
Researchers have identified hundreds of genes with significant stroke-driven changes and likely relevance in human strokes. The study found alterations in sphingolipid production, which are involved in regulating blood vessels, and pinpointed several molecular pathways that can be targeted for stroke treatment.
Researchers at MIT have found a way to reverse neurodegeneration and symptoms of Alzheimer's disease by interfering with an overactive brain enzyme called CDK5. The peptide treatment reduced neurodegeneration, DNA damage, and improved behavior in mice with Alzheimer's.
Scientists discovered that deleting a protein called sphingosine kinase 2 (SphK2) reprograms the tumor microenvironment, decreasing S1P levels and increasing p53 tumor suppressor gene accumulation. This creates an inhospitable environment for aggressive breast tumors.
A research team led by the University of Cincinnati's Atsuo Sasaki aims to understand how an enzyme regulates lysosomal function based on energy molecule GTP. This study could lead to new treatments for cancer, neurodegenerative diseases and anti-aging.
A novel database, CycPeptMPDB, has been created to facilitate the development of drugs based on cyclic peptides. The database contains information on thousands of cyclic peptides and their membrane permeability values, enabling researchers to select candidate peptides that can penetrate human cell membranes.
A novel small molecule, MK-8722, has been shown to trigger improved muscle health in mice with muscular dystrophy by activating AMPK. This finding highlights the potential of this class of AMPK activators as a cost-effective and efficacious method for DMD treatment.
Researchers at the University of Chicago have found that adding small molecules called immunomodulators to vaccine adjuvants can regulate the body's response to vaccines, reducing negative side effects. The study increased antibody response in flu vaccine models and reduced inflammation in typhoid vaccine models.